Abstract
C Baggott, HK Reddel, J Hardy. Eur Respir J. 2020;55(4):1902073 Symptom-driven low-dose inhaled corticosteroid–formoterol use is safe and effective in mild asthma and has been recommended as one of the preferred treatment regimens at steps 1 and 2 in the 2019 update of the Global Initiative for Asthma (GINA). However, there are no data on patient preferences for this regimen. The purpose of this study was to investigate patient preferences between two regimens: symptom-driven budesonide-formoterol versus maintenance inhaled corticosteroid (ICS) with a separate as-needed reliever inhaler. This study …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have